Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 19/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25335716 | 0.91 | KRAS (0.50) | KRASMAPK3MAPK1 | |
| SCHEMBL24536826 | 0.91 | KRAS (0.52) | KRAS | |
| SCHEMBL29680489 | 0.91 | KRAS (0.52) | KRAS | |
| SCHEMBL25336180 | 0.80 | KRAS (0.53) | KRAS | |
| SCHEMBL25336186 | 0.80 | KRAS (0.53) | KRAS | |
| SCHEMBL25335201 | 0.80 | KRAS (0.64) | KRASMAPK3MAPK1 | |
| SCHEMBL25336092 | 0.80 | KRAS (0.54) | KRAS | |
| SCHEMBL29679897 | 0.79 | KRAS (0.55) | KRASMAPK3MAPK1 | |
| SCHEMBL27394454 | 0.79 | KRAS (0.64) | KRASMAPK3MAPK1 | |
| SCHEMBL25334929 | 0.78 | KRAS (0.66) | KRASMAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472980-A2 | QUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023150284-A2 | QUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025907-A1 | QUINAZOLINE PAN-KRas INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885MAPK3 306/4885MAPK1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.